12
Fri, Jul
68 New Articles

EY Law advises Rohto on Acquisition of Sigmapharm/MoNo Chem-Pharm Group

EY Law advises Rohto on Acquisition of Sigmapharm/MoNo Chem-Pharm Group

Austria
Tools
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

EY Law has advised Rohto on its acquisition of the Austrian Sigmapharm/MoNo chem-pharm group.

The deal is valued at approximately EUR 30 million.

Based in Osaka and listed on the Tokyo Stock Exchange, Rohto specializes in the research, production, and distribution of over-the-counter medicines, particularly in the area of eye drops.

According to EY law, "Rohto Pharmaceutical will acquire 51% of the parent company of the Sigmapharm group, located in Austria. This investment aims to further expand Sigmapharm’s production capacities and distribution network and significantly strengthen Rohto Pharmaceutical’s presence in the European market." 

The EY Law team included Partner Mario Gall, Attorneys at Law Sonam Schima, Clara Messner-Kreuzbauer, David Konrath, and Andreas Lopatka-Sint, and Associates Laura Graf, Paul Kness, and Lukas Wandl.

EY Law was unable to provide additional information on the matter.

Our Latest Issue